MALVERN, Pa., Feb. 23, 2016 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of medical and regulatory affairs executives, as the Company advances in its assessment of several unique drug candidates.
ZTlido™ (lidocaine patch 1.8%) is the Company's first product, a next-generation patch being developed for the treatment of postherpetic neuralgia, or after-shingles pain. SCILEX's new drug application for ZTlido™ was accepted by the FDA in September and has a PDUFA date in the second quarter of 2016.
The new hires include Dr. Kalpana Patel as Senior Director of Medical Affairs and Ms. Christine Rosser as Senior Director of Regulatory Affairs. Mr. Damon Burrows, JD will also join SCILEX as Vice-President, General Counsel and Corporate Secretary.
"These hires add to the expertise of our growing team, and boost our capacity as we explore the commercialization of several differentiated pain treatment products," said Anthony Mack, Chief Executive Officer of SCILEX. "Their industry knowledge and commercial acumen ensures SCILEX is well-positioned to realize its ambitions."
Dr. Kalpana Patel has more than 16 years of Medical Affairs experience, developing key projects for global companies such as Johnson & Johnson and Pfizer. She has clinical and research expertise across specialties which include Pain Management, Critical Care and Surgery. Dr. Patel has held senior clinical roles at hospitals in New York, and published several research papers. She holds a Bachelor of Science and a Doctor of Pharmacy degree from the Rutgers College of Pharmacy in New Jersey.
Ms. Rosser has more than 20 years of pharmaceutical regulatory expertise at global pharma companies including Pfizer, Endo Pharmaceuticals, and other well-known pharmaceutical firms. Her previous roles include director of U.S. regulatory advertising and promotion at Pfizer, promotional regulatory affairs director at Endo, and director of regulatory affairs at the since-acquired Auxilium Pharmaceuticals. She earned a Bachelor of Science in Biology from Pennsylvania's Albright College and a Master of Science in Cell Biology and Biotechnology from the University of the Sciences in Philadelphia.
Mr. Burrows has spent his career in life sciences and healthcare, having held senior legal positions at Allergan and Hoffmann-La Roche (now Genentech). He began his career at Jenkens & Gilchrist and later was counsel at Baker, Donelson, Bearman & Caldwell. As part of Mr. Burrows' role at Allergan, he was lead legal counsel for a number of global functions including, Research and Development, Manufacturing, Regulatory, Commercial and Global Strategic Marketing and Health Outcomes. At Hoffmann-La Roche, he was lead counsel for multiple drug development and commercial programs. Mr. Burrows holds a Bachelor of Science from Southwestern Christian University in Oklahoma and his Juris Doctor from the Catholic University of America in Washington D.C.
About SCILEX Pharmaceuticals
SCILEX Pharmaceuticals, Inc., located in Malvern, PA, responsibly develops and brings branded pharmaceutical products to market using groundbreaking technologies that maximize quality of life for all. We are uncompromising in our focus to become the global pharmaceutical leader committed to social, environmental, economic, and ethical responsibility. Dedicated to using our internal partnerships, we deliver the next generation of trailblazing products that are responsible by design. The Company's lead product under development, ZTlido™ (lidocaine patch 1.8%), is a next-generation branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain. For more information visit www.scilexpharma.com. ZTlido™ is a trademark owned by SCILEX Pharmaceuticals, Inc. A proprietary name review by the FDA is planned.
SOURCE SCILEX Pharmaceuticals, Inc.